Co-Diagnostics (CODX) Set to Release Quarterly Earnings on Thursday

Co-Diagnostics (NASDAQ:CODX) is projected to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($1.25) per share and revenue of $0.17 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.00) by $1.54. Co-Diagnostics had a negative return on equity of 210.99% and a negative net margin of 6,531.77%. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million.

Co-Diagnostics Stock Performance

Shares of Co-Diagnostics stock opened at $0.36 on Thursday. Co-Diagnostics has a twelve month low of $0.35 and a twelve month high of $13.54. The firm has a market cap of $3.19 million, a P/E ratio of -0.04 and a beta of 3.15. The firm’s 50-day simple moving average is $0.93 and its 200-day simple moving average is $2.17.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CODX. Maxim Group upgraded Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 18th. Weiss Ratings raised shares of Co-Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 27th. Finally, Wall Street Zen raised Co-Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Co-Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $45.00.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases.